Literature DB >> 16596194

Differential expression of alternatively spliced mRNA forms of the insulin-like growth factor 1 receptor in human neuroendocrine tumors.

Lorenza Vitale1, Luca Lenzi, Shane A Huntsman, Silvia Canaider, Flavia Frabetti, Raffaella Casadei, Federica Facchin, Paolo Carinci, Maria Zannotti, Domenico Coppola, Pierluigi Strippoli.   

Abstract

The activation of the insulin-like growth factor 1/IGF1 receptor system (IGF1/IGF1R) is a critical event in the transformation and tumorigenicity processes in a wide variety of human tumors. The IGF1/IGF1R system has been recently studied in carcinoid tumors that often arise in the gastrointestinal tract; these tumors are characterized by hypersecretion of bioamines and neuropeptides, leading to functional tumor disease. Two alternatively spliced IGF1R mRNA transcripts have been described to differ by only three nucleotides (CAG) in the coding sequence, resulting in an amino-acid change from the originally described Thr-Gly to an Arg in the extracellular portion of the receptor beta subunit. In transfected Chinese hamster ovary cells, the form without CAG (CAG-) exhibited an approximate 2-fold increase in IGF1 stimulation of activities required for its mitogenic properties. In this study, we examine the relative expression of the two IGF1R mRNA isoforms by a semiquantitative RT-PCR approach using highly standardized conditions, beta-2 microglobulin (B2M) as a reference gene and gel imaging analysis. We analyzed a large series of human neuroendocrine tumors (32 samples) and 9 normal tissues. A significant higher expression of both isoforms in the tumor samples (approximately 2-fold increase) was found, while a constant CAG+/CAG- IGF1R mRNA isoforms of an approximate 3:1 ratio was observed in all tumoral and normal cell types studied. The phylogenetic study of the IGF1R locus in several species suggests that human IGF1R CAG- mRNA isoform is evolutionarily more recent compared to the IGF1R CAG+ mRNA isoform and it could be used by the splicing apparatus at this intron/exon junction with a lower efficiency. This study highlights the relevance of IGF1R mRNA expression in neuroendocrine tumor cells, and the constant presence of 'subtle' alternative splicing for the IGF1R locus.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16596194

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  12 in total

1.  Therapy: Blockade of IGF-1R-not effective in neuroendocrine tumours.

Authors:  Steven K Libutti
Journal:  Nat Rev Endocrinol       Date:  2013-06-04       Impact factor: 43.330

Review 2.  Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives.

Authors:  Michael Höpfner; Detlef Schuppan; Hans Scherübl
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

Review 3.  Medical treatment for gastro-entero-pancreatic neuroendocrine tumours.

Authors:  Rossana Berardi; Francesca Morgese; Mariangela Torniai; Agnese Savini; Stefano Partelli; Silvia Rinaldi; Miriam Caramanti; Consuelo Ferrini; Massimo Falconi; Stefano Cascinu
Journal:  World J Gastrointest Oncol       Date:  2016-04-15

4.  Complexity of bidirectional transcription and alternative splicing at human RCAN3 locus.

Authors:  Federica Facchin; Lorenza Vitale; Eva Bianconi; Francesco Piva; Flavia Frabetti; Pierluigi Strippoli; Raffaella Casadei; Maria Chiara Pelleri; Allison Piovesan; Silvia Canaider
Journal:  PLoS One       Date:  2011-09-22       Impact factor: 3.240

5.  Mapping a new spontaneous preterm birth susceptibility gene, IGF1R, using linkage, haplotype sharing, and association analysis.

Authors:  Ritva Haataja; Minna K Karjalainen; Aino Luukkonen; Kari Teramo; Hilkka Puttonen; Marja Ojaniemi; Teppo Varilo; Bimal P Chaudhari; Jevon Plunkett; Jeffrey C Murray; Steven A McCarroll; Leena Peltonen; Louis J Muglia; Aarno Palotie; Mikko Hallman
Journal:  PLoS Genet       Date:  2011-02-03       Impact factor: 5.917

6.  GeneBase 1.1: a tool to summarize data from NCBI gene datasets and its application to an update of human gene statistics.

Authors:  Allison Piovesan; Maria Caracausi; Francesca Antonaros; Maria Chiara Pelleri; Lorenza Vitale
Journal:  Database (Oxford)       Date:  2016-12-26       Impact factor: 3.451

7.  Can insulin-like growth factor 1 (IGF-1), IGF-1 receptor connective tissue growth factor and Ki-67 labelling index have a prognostic role in pulmonary carcinoids?

Authors:  Georgios A Kanakis; Lars Grimelius; Dimitrios Papaioannou; Gregory Kaltsas; Apostolos V Tsolakis
Journal:  Oncotarget       Date:  2018-04-27

8.  Sequence, "subtle" alternative splicing and expression of the CYYR1 (cysteine/tyrosine-rich 1) mRNA in human neuroendocrine tumors.

Authors:  Lorenza Vitale; Flavia Frabetti; Shane A Huntsman; Silvia Canaider; Raffaella Casadei; Luca Lenzi; Federica Facchin; Paolo Carinci; Maria Zannotti; Domenico Coppola; Pierluigi Strippoli
Journal:  BMC Cancer       Date:  2007-04-18       Impact factor: 4.430

Review 9.  PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Franziska Briest; Patricia Grabowski
Journal:  Theranostics       Date:  2014-01-29       Impact factor: 11.556

10.  Identification of minimal eukaryotic introns through GeneBase, a user-friendly tool for parsing the NCBI Gene databank.

Authors:  Allison Piovesan; Maria Caracausi; Marco Ricci; Pierluigi Strippoli; Lorenza Vitale; Maria Chiara Pelleri
Journal:  DNA Res       Date:  2015-11-17       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.